Loading
Personalis' whole-genome blood test for leftover cancer, which tracks up to 1,800 of the tumour's own mutations and is Medicare-covered in breast and lung cancer.
NeXT Personal Dx is Personalis' tumour-informed residual disease test. Whole-genome sequencing of tumour and normal designs a panel of up to 1,800 variants, and Personalis states detection down to about one part per million of ctDNA with specificity above 99.9%. Medicare covered it on 7 November 2025 (effective 7 October 2025) for surveillance after stage II and III breast cancer, then in the first quarter of 2026 for surveillance in stage I-III non-small cell lung cancer, on 12 May 2026 for monitoring immunotherapy in late-stage solid tumours, and on 19 May 2026 for monitoring neoadjuvant therapy in stage II-III triple-negative or HER2-positive breast cancer. Tempus has sold the test since a partnership in November 2023, listing it as xM (NeXT Personal Dx), and on 20 July 2026 Personalis agreed to be acquired by Tempus; Personalis' shareholders are due to vote on 30 November 2026. It is a laboratory-developed test performed in Personalis' CLIA-certified laboratory and has not been cleared or approved by the FDA.
Whole-genome sequencing of the tumour and a matched normal blood sample builds a personalised signature of up to 1,800 variants, which is then tracked in plasma at sequencing depths of up to about 100,000-fold.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NeXT Personal Dx" OR ABSTRACT:"NeXT Personal Dx" OR TITLE:"NeXT Personal" OR ABSTRACT:"NeXT Personal" OR TITLE:"Personalis NeXT Personal" OR ABSTRACT:"Personalis NeXT Personal" OR TITLE:"Tempus xM NeXT Personal Dx" OR ABSTRACT:"Tempus xM NeXT Personal Dx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NeXT Personal Dx, not a curated reading list.
Shares Tempus xM for MRD (tumour-naive), RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment) and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag test.
Shares Tempus AI, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Triple-negative breast cancer (TNBC) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/